American depositary receipts of European stocks were trading 0.1% higher at 1,137.01 on the S&P/BNY Mellon Europe Select ADR Index on Wednesday.
In continental Europe, the gainers were led by biopharmaceutical firm Biofrontera (BFRA) and semiconductor company Sequans Communications (SQNS), which climbed 11% and 4.7%, respectively. They were followed by hotel booking site trivago (TRVG) and biopharmaceutical company Orphazyme (ORPH), which gained 3.7% and 2.7%, respectively.
The decliners in continental Europe were led by biotech firm BioNTech (BNTX) and biopharmaceutical company Grifols (GRFS), which declined 3.3% and 2.5%, respectively. They were followed by optical bonding company VIA optronics (VIAO) and biopharmaceutical firm Atai Life Sciences (ATAI), which lost 2.4% and 2.2%, respectively.
In the UK and Ireland, the gainers were led by cruise line operator Carnival Corp. (CUK) and biopharmaceutical firm Mereo BioPharma Group (MREO), which added 6.4% and 5.8%, respectively. They were followed by biopharmaceutical firm Bicycle Therapeutics (BCYC) and biotech firm Autolus Therapeutics (AUTL), which gained 4.4% and 3.9%, respectively.
The decliners in the UK and Ireland were led by medical device maker EDAP TMS (EDAP) and biopharmaceutical firm Adaptimmune Therapeutics (ADAP), which declined 2.2% and 2.1%, respectively. They were followed by biopharmaceutical company Amarin (AMRN) and educational publishing firm Pearson (PSO), which lost 1.6% and 1.4%, respectively.